Most Read Articles
Roshini Claire Anthony, 02 Feb 2018

The use of weight loss medications for at least 1 year did little to improve cardiometabolic risk factors in obese adults, according to a systematic review and meta-analysis.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
26 Feb 2019
Oral fluoxetine confers beneficial effects in the management of adult and adolescent amblyopia, suggests a recent study.
19 Feb 2019
Preprandial administration of metformin successfully and safely reduces postprandial plasma triglyceride levels, a new study has shown.

Organ damage, anti-dsDNA antibodies predict belimumab efficacy in lupus

11 Jul 2019

Belimumab treatment for systemic lupus erythematosus (SLE) may induce low disease activity (LDA) and clinical remission in patients with limited or no organ damage, as well as with positive antidouble stranded DNA (anti-dsDNA) titres, according to a study.

The study used data from the BLISS-52 and BLISS-76 trials and included 563 SLE patients (mean age, 37.9 years; 95.7 percent female) who received belimumab 10 mg/kg. Researchers used logistic regression to evaluate the performance of baseline factors in predicting achievement of LDA (assessed using Lupus Low Disease Activity State [LLDAS]) or clinical remission (defined as SLE Disease Activity Index 2000 score of 0) at week 52 from treatment initiation.

Organ damage (assessed using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index [SDI]) reduced the likelihood of attaining LDA (SDI >0: odds ratio (OR), 0.44, 95 percent CI, 0.22–0.90; p=0.024) and the primary LLDAS condition (ie, SLEDAI-2K 4 with no renal activity, pleurisy, pericarditis or fever; SDI >1: OR, 0.46, 0.27–0.77; p=0.004). The association between organ damage and failure to achieve the primary LLDAS condition was attributed mainly to cognitive impairment/psychosis prior to belimumab initiation.

Baseline SDI scores >1 also predicted failure to attain clinical remission (OR, 0.53, 0.30–0.94; p=0.030), with cutaneous damage largely driving this association.

On the other hand, anti-dsDNA positivity increased the probability of attaining clinical remission, along with reduced prednisone intake (7.5 mg/day), by about 80 percent (OR, 1.82, 1.08–3.06; p=0.025). However, cardiovascular damage reduced the probability of such an outcome (OR, 0.13, 0.02–0.97; p=0.047).

The associations observed were independent of age, SLE disease duration or SLE activity grade, the researchers noted, adding that the data overall have important clinical implications with respect to optimization of the use of belimumab.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 02 Feb 2018

The use of weight loss medications for at least 1 year did little to improve cardiometabolic risk factors in obese adults, according to a systematic review and meta-analysis.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
26 Feb 2019
Oral fluoxetine confers beneficial effects in the management of adult and adolescent amblyopia, suggests a recent study.
19 Feb 2019
Preprandial administration of metformin successfully and safely reduces postprandial plasma triglyceride levels, a new study has shown.